Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune Thyroid Disease and Metabolic Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TSHR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TSHR ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View TSHR Products |
| Gene Delivery | TSHR Lentivirus Premade Particles / ORF clones Full-length GPCR for stable cell line construction. cAMP signaling preserved. Cell-based assays are the only way to preserve conformation. |
View TSHR Products |
| Benchmark Ab | Anti-TSHR Benchmark Antibody (Clone K1-70) Recombinant blocking antibody positive control for blocking assays. |
View TSHR Products |
| Validator | TSHR siRNA Set For knockdown verification and specificity controls. |
View TSHR Products |
| Counter-screening | LHCGR ECD-Fc / Full-Length Lentivirus Critical for glycoprotein receptor selectivity assays. |
View LHCGR Products |
| Related Target: IGF1R | Synergistic pathway in Thyroid Eye Disease (TED) crosstalk. | View IGF1R Products |
| Related Target: TPO | Thyroid peroxidase, key autoimmune thyroiditis marker. | View TPO Products |
| Related Target: TSH | Natural ligand for competitive binding assays. | View TSH Products |
| Related Target: MC4R | Metabolic pathway synergist for obesity combination therapy. | View MC4R Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Conformation | Lentivirus premade particles available for rapid stable cell line generation. |
| Glycosylation-dependent Binding | Antigens are strictly HEK293 Expressed (Native Glycosylation) with Theoretical MW validation. |
| GPCR Conformational Integrity | Lentivirus-delivered full-length TSHR preserves native folding and cAMP coupling; suitable for flow cytometry and calcium flux assays. |
| LHCGR Selectivity (Glycoprotein hormone receptor family cross-reactivity) | Human/Mouse/Cyno LHCGR ortholog proteins available with >95% purity; strict sequence verification by mass spec for counter-screening panels. |
| Species Cross-reactivity (Preclinical Safety) | Human/Cynomolgus/Mouse TSHR ECD proteins with matched glycosylation profiles (HEK293 expression). |
| Agonist vs Antagonist Differentiation | Sequence-verified TSH ligand protein available as reference agonist for functional assay calibration. |
| Lack of Controls | Clinical Benchmark Antibodies included for cAMP assay calibration. |
| False Positives | Sequence Verified targets and Validated siRNA included for specificity checks. |
Live TSHR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TSHR therapeutics is intensifying, with major players shifting focus from systemic immunosuppressants to highly specific monoclonal antibodies and small molecule antagonists. As first-generation therapies targeting downstream or parallel pathways (like IGF-1R in Thyroid Eye Disease) reach the clinic, the next wave of R&D is targeting direct TSHR antagonism to halt the root cause of Graves' disease and associated ophthalmopathy. Furthermore, the field is bifurcating into two distinct modalities: antagonist antibodies for Graves' disease and TED, and small molecule agonists for metabolic disorders including obesity and MASH. This dual-track development reflects the broad therapeutic potential of TSHR modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Blocking) | Worg Pharma (K1-70), Roche, Immunovant | Graves' Disease, TED | Receptor Blocking Assay; need Lentivirus for cell line and LHCGR selectivity panel. |
| Small Molecule (Antagonist) | Various Biotechs | Graves' Hyperthyroidism | cAMP Accumulation Assay; need intact GPCR conformation. |
| Small Molecule (Agonist) | Novartis, Structure Therapeutics | Obesity, MASH | cAMP Signaling Assay; need stable full-length TSHR cell lines. |
| Peptide Antagonist | Apitope | Autoimmune Thyroiditis | Epitope Mapping; need mutant ECD proteins with domain deletions. |
| Bispecific | Preclinical stage | Refractory TED | Crosstalk Validation; need TSHR and IGF1R reagents. |
| ADC/Radioligand | Academic Consortia | Thyroid Cancer Imaging | Internalization Assay; need high-affinity ECD-Fc bait. |